NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology...
Southlake, Texas, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the...
WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has...
LITTLETON, Colo., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology...
Disc will obtain exclusive rights to MWTX-003 and other novel anti-TMPRSS6 antibodies in the United States, Europe and other territories...
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is...
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"),...
Myrlid AS har i dag, 20. januar 2023, solgt 450 000 aksjer i PCI Biotech Holding ASA ("Selskapet"). Som følge...
CancerVAX CEO Ryan Davies speaks with Todd Kinard, a leading biotech intellectual property (IP) expert about how patents can be...
NFL Biosciences: CESTO II trial progressing on schedule Nine clinical sites active: more than 72% of the clinical trial participants...
Press Release Ecully, 20th January 2023 – 8:00 am 2022 revenues up 73% to €7.4 million "2022 financial year represents...
Hyloris targets regulatory approval in Europe, with possible further extensionsAbout 5% of hospitalized patients is diagnosed with hypophosphatemia, with part...
NEWS RELEASE –REGULATED INFORMATION20 JANUARY 2023, 1:00 am ET / 7:00 am CET MDxHealth Provides Updated and Supplemental...
NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5%...
TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R),...
International Corporate Executive and Attorney Alberto Eguiguren Correa Appointed to Board of Directors MIAMI and BARRANQUILLA, Colombia, Jan. 19, 2023...
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular...
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administrationSAN DIEGO, Jan. 19, 2023...
FDA sets PDUFA date of May 22, 2023SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:...